LPAR1 and metabolic disease: Targeting the ATX-LPA-LPA1-6 pathway holds therapeutic potential, as this signaling axis may promote the development of metabolic disorders through multiple mechanisms involving inflammation, fibrosis, and impaired mitochondrial function and PPARγ activation.